Raymond James Maintains Strong Buy on Apellis Pharmaceuticals, Raises Price Target to $106
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Steven Seedhouse has reaffirmed a Strong Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) and increased the price target from $67 to $106. This adjustment reflects a positive outlook on the company's stock.
January 11, 2024 | 4:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Raymond James analyst Steven Seedhouse maintains a Strong Buy rating on Apellis Pharmaceuticals and raises the price target from $67 to $106, indicating a bullish outlook on the stock.
The increase in price target by a reputable analyst like Steven Seedhouse from Raymond James typically signals a strong conviction in the company's future performance and growth potential. This can often lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100